気管支炎治療の世界市場 - 2022年～2029年

当レポートでは、世界の気管支炎治療市場について調査し、市場の概要とともに、薬剤クラス別、タイプ別、流通チャネル別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 気管支炎治療市場の調査手法と範囲

第2章 気管支炎治療市場-市場の定義と概要

第3章 気管支炎治療市場-エグゼクティブサマリー

• 薬剤クラス別市場内訳
• タイプ別市場内訳
• 流通チャネル別市場内訳
• 地域別市場内訳

第4章 気管支炎治療市場-市場力学

• 市場に影響を与える要因
  • 促進要因
  • 抑制要因
  • 市場機会
  • 影響分析

第5章 気管支炎治療市場-業界分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• アンメットニーズ

第6章 気管支炎治療市場-COVID-19分析

第7章 気管支炎治療市場-薬剤クラス別

• イントロダクション
• 市場規模分析、および前年比成長分析（％）、薬剤クラス別
• 市場魅力指数、薬剤クラス別
  • 気管支拡張薬
  • 抗生物質
  • 抗炎症薬
  • その他

第8章 気管支炎治療市場-タイプ別

• イントロダクション
• 市場規模分析、および前年比成長分析（％）、タイプ別
• 市場魅力指数、タイプ別
  • 急性気管支炎
  • 慢性気管支炎

第9章 気管支炎治療市場-流通チャネル別

• イントロダクション
  • 市場規模分析、および前年比成長分析（％）、流通チャネル別
  • 市場魅力指数、流通チャネル別
• 病院薬局
  • イントロダクション
  • 市場規模分析、100万米ドル（2020年～2029年）、および対前年比成長分析（％）（2021年～2029年）
• 小売薬局
• その他

第10章 気管支炎治療市場-地域別

• イントロダクション
  • 市場規模分析、100万米ドル（2020年～2029年）、および対前年比成長分析（％）（2021年～2029年）、地域別
  • 市場魅力指数、地域別
• 北米
• 欧州
• 南米
• アジア太平洋
• 中東・アフリカ

第11章 気管支炎治療市場-競合情勢

• 主な発展と戦略
• 企業シェア分析
• 製品のベンチマーク

第12章 気管支炎治療市場-企業プロファイル

• AstraZeneca plc
• Cadila Healthcare Limited
• Novartis AG
• GlaxoSmithKline plc
• Dr. Reddy's Laboratories Ltd.
• SANOFI S.A
• Boehringer Ingelheim International GmbH
• Lupin Limited
• Teva Pharmaceuticals USA, Inc.

第13章 気管支炎治療市場-DataM

Market Overview

The global bronchitis treatment market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Bronchitis is an inflammation of the bronchial tube lining, transporting air to and from the lungs. Bronchitis causes thickened mucus to be coughed up, which can be discolored. Bronchitis can be acute or chronic.

Market Dynamics

The factors influencing the bronchitis treatment market are the rising pollution levels and the increasing prevalence of chronic obstructive pulmonary disease (COPD).

The rising level of pollution is expected to drive the global bronchitis treatment market in the forecast period

Chronic bronchitis is a common clinical condition marked by persistent cough and sputum production for at least 3 months over two or more years. Estimates of prevalence in the general adult population range from 3.5 to 27%. Bronchitis is caused by inhaling infectious or physicochemical agents through the airway. Environmental factors play a role in the progression of bronchitis.

In all studies, chronic bronchitis symptoms were more common in areas with higher particulate air pollution. Prospective studies in a larger number of geographical areas are needed to confirm that current urban air pollution is linked to the occurrence of chronic bronchitis. Sulfates, carbon materials, nitrates, trace elements, and water are the main components of particulate matter. Sulfur dioxide (SO2) and respirable particulate matter diameter less than 10 microns (PM10) are the most blamed pollutants for contamination and health effects. As a result, they are considered first in routine measurements. Annual Arithmetic Mean for Sulfur Dioxide (SO2) 0:03 ppm(80g/m3), 24-hour limit is 0:14 ppm (365g/m3), Suspended Particulate Matter (PM10) limit value for the annual arithmetic average is 50 g/m3, boundary value for 24 hours is 150g/m3 according to NAAQS (National Ambient Air Quality Standards). Air pollution has a greater impact on children than it does on adults. Because the lungs continue to develop until six to eight, 80 percent of alveoli form after birth.

The problems associated with bronchitis treatment are expected to hamper the market growth

Lack of approved bronchitis drugs, strict regulatory policies, high costs associated with research and development, and preference for alternative treatment options are factors limiting the growth of the bronchitis treatment market over the forecast period. Treatment costs rise as the disease progresses, and other factors such as age, chronic Pseudomonas aeruginosa infection, exacerbations, and other admissions are considered. The average annual cost per patient with bronchitis was €4,671.00 in a study conducted in Spain, and this cost doubled with each increase in severity. Moreover, the side effects associated with the drugs are expected to hamper the market growth. For instance, nausea, vomiting, and diarrhea are the most common bronchitis side effects. Weight gain and mood swings are possible side effects of some drug classes, such as corticosteroids, while bronchodilators can cause heart palpitations and upset stomach.

COVID-19 Impact Analysis

The onset of the COVID-19 pandemic has resulted in a reduction in patient visits, reducing the number of patients seeking bronchitis treatment, affecting the market growth. For instance, according to a September 2020 article titled "Reduction in ambulatory visits for acute, uncomplicated bronchitis: an unintended but welcome result of the coronavirus disease 2019 (COVID-19) pandemic," the COVID-19 pandemic has resulted in an overall net reduction in ambulatory adults seeking care for bronchitis in the health system while challenging many other aspects of antimicrobial stewardship. As a result, during the early stages of the pandemic, COVID-19 had a negative impact on the market.

Segment Analysis

The bronchodilators segment is expected to dominate the market growth in the forecast period

The bronchodilator segment is expected to account for a significant market. Bronchodilators are medications that open the airway passages and expand the windpipe, making it easier to breathe for people with lung infections, bronchial asthma, and chronic obstructive pulmonary disease (COPD). Bronchodilators are the first-line treatment for bronchitis because they clear the airway obstruction, an important parameter in chronic bronchitis patients' breathing.

Furthermore, major factors driving the market segment's growth include the rising incidence of respiratory diseases, the rising prevalence of smoking, and the rising number of product approvals. As the number of respiratory diseases rises, the demand for bronchodilators is expected to rise. For instance, according to a February 2022 article published by the National Center for Bio, "Acute Bronchitis," it is estimated that 5% of the general population suffers from acute bronchitis each year, resulting in more than 10 million office visits. As a result, as the prevalence of bronchitis rises, so does the demand for bronchitis treatment. On 14th February 2022, the US FDA approved Lupin Limited's generic version of Brovana (arformoterol tartrate) for treating bronchoconstriction in people with chronic obstructive pulmonary disease (COPD) (COPD). Brovana's active ingredient is a bronchodilator, which causes the airways to relax and widen, reducing bronchoconstriction.

Geographical Analysis

North America region is expected to hold the largest market share in the global bronchitis treatment market

The increase in the incidence of bronchitis, a rising smoking trend among the young generation, and an increase in the number of strategic initiatives taken by market players are expected to drive market growth. For instance, according to the CDC, 5% of adults in the United States were diagnosed with chronic obstructive pulmonary disease (COPD), emphysema, or chronic emphysema in 2020, according to a February 2022 update. As a result, COPD is linked to bronchitis, so there is a high demand for bronchitis treatment. On 4th June 2021, Lupin launched Arformoterol, a generic inhalation product, to treat chronic bronchitis in the United States market. As a result of these developments, more such products are expected to be developed and approved to treat bronchitis, boosting the country's market growth in the coming years.

Competitive Landscape

The global bronchitis treatment market is highly competitive with mergers, acquisitions, and product launches. Some key players are AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Dr. Reddy's Laboratories Ltd., Sanofi S.A, Boehringer Ingelheim International GmbH, Lupin Limited, Cadila Healthcare Limited, Teva Pharmaceuticals USA, Inc.

AstraZeneca plc

Overview: AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company headquartered in Cambridge, England's Cambridge Biomedical Campus.

Product Portfolio: Roflumilast is a drug used to treat and prevent the symptoms of chronic lung disease, such as wheezing and shortness of breath (chronic obstructive pulmonary disease-COPD, which includes bronchitis).

In February 2022, Zydus, a Cadila Healthcare subsidiary received final approval from the US Food and Drug Administration to market roflumilast tablets in the 500mcg strength and tentative approval for roflumilast tablets. In patients with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations, the tablets are indicated as a treatment to reduce the risk of exacerbations.

Why Purchase the Report?

• Visualize the composition of the global bronchitis treatment composition market segmentation by class of drugs, type, and distribution channel, highlighting the key commercial assets and players.

• Identify commercial opportunities in global bronchitis treatment market by analyzing trends and co-development deals.

• Excel data sheet with thousands of data points of global bronchitis treatment market- level 4/5 segmentation.

• PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

• Product mapping in excel for the key product of all major market players

The global bronchitis treatment market report would provide an access to an approx. 45+market data table, 40+figures and 185 pages.

Target Audience

• Service Providers/ Buyers
• Industry Investors/Investment Bankers
• Education & Research Institutes
• Research Professionals
• Emerging Companies
• Manufacturers

Table of Contents

1. Bronchitis Treatment Market Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Bronchitis Treatment Market- Market Definition and Overview

3. Bronchitis Treatment Market- Executive Summary

• 3.1. Market Snippet By Class of Drugs
• 3.2. Market Snippet By Type
• 3.3. Market Snippet By Distribution Channel
• 3.4. Market Snippet By Region

4. Bronchitis Treatment Market-Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers:
    • 4.1.1.1. The rising level of pollution
  • 4.1.2. Restraints:
    • 4.1.2.1. The problems associated with bronchitis treatment
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Bronchitis Treatment Market- Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Unmet Needs

6. Bronchitis Treatment Market- COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. Bronchitis Treatment Market- By Class of Drugs

• 7.1. Introduction
• 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Class of Drugs
• 7.3. Market Attractiveness Index, By Class of Drugs
  • 7.3.1. Bronchodilator*
    • 7.3.1.1.1. Introduction
    • 7.3.1.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3.2. Antibiotics
  • 7.3.3. Anti-inflammatory Drugs
  • 7.3.4. Others

8. Bronchitis Treatment Market-By Type

• 8.1. Introduction
• 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
• 8.3. Market Attractiveness Index, By Type
  • 8.3.1. Acute Bronchitis
    • 8.3.1.1.1. Introduction
    • 8.3.1.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3.2. Chronic Bronchitis

9. Bronchitis Treatment Market- By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospital Pharmacies
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. Retail Pharmacies
• 9.4. Other

10. Bronchitis Treatment Market- By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Class of Drugs
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Class of Drugs
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Class of Drugs
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Class of Drugs
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Class of Drugs
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Bronchitis Treatment Market- Competitive Landscape

• 11.1. Key Developments and Strategies
• 11.2. Company Share Analysis
• 11.3. Product Benchmarking

12. Bronchitis Treatment Market- Company Profiles

• 12.1. AstraZeneca plc *
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. Cadila Healthcare Limited
• 12.3. Novartis AG
• 12.4. GlaxoSmithKline plc
• 12.5. Dr. Reddy's Laboratories Ltd.
• 12.6. SANOFI S.A
• 12.7. Boehringer Ingelheim International GmbH
• 12.8. Lupin Limited
• 12.9. Teva Pharmaceuticals USA, Inc.

LIST NOT EXHAUSTIVE

13. Bronchitis Treatment Market- DataM

• 13.1. Appendix
• 13.2. About Us and Services
• 13.3. Contact Us